AQR Capital Management LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

AQR Capital Management LLC reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,624 shares of the biopharmaceutical company’s stock after selling 3,422 shares during the quarter. AQR Capital Management LLC’s holdings in Amicus Therapeutics were worth $869,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in FOLD. Xponance Inc. boosted its stake in shares of Amicus Therapeutics by 5.3% during the 2nd quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 936 shares in the last quarter. American International Group Inc. raised its holdings in Amicus Therapeutics by 0.9% during the fourth quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock worth $2,004,000 after purchasing an additional 1,298 shares during the last quarter. Arizona State Retirement System raised its holdings in Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock worth $615,000 after purchasing an additional 1,577 shares during the last quarter. Principal Financial Group Inc. boosted its position in Amicus Therapeutics by 1.1% during the second quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock worth $2,389,000 after purchasing an additional 2,737 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Amicus Therapeutics by 6.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,471 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 2,918 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,382,718.34. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 22,500 shares of company stock valued at $244,875. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on FOLD shares. Morgan Stanley cut their price target on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Friday, September 20th. JPMorgan Chase & Co. cut their price objective on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 16th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Stock Up 4.5 %

Shares of NASDAQ FOLD opened at $10.50 on Friday. The firm has a market cap of $3.11 billion, a P/E ratio of -21.43 and a beta of 0.69. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The firm’s 50 day moving average price is $11.11 and its 200 day moving average price is $10.58.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business’s revenue was up 34.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.15) earnings per share. As a group, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.07 earnings per share for the current year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.